Advertisement

Syndax Pharmaceuticals Inc., a cancer therapeutics developer in Waltham, has been granted a patent from the European Patent Office for an oral HDAC inhibitor, called entinostat, to treat metastatic breast cancer and advanced non-small cell lung cancer. The U.S. patent office granted the company a patent for entinostat in June.

Entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases (HDAC).

SOURCE

Advertisement
Advertisement